Found 562 results for Dermatology

Webinars

button
27 Jun 24
button
button
button
25 Jun 24
button

Videos

27 May

Periorbital Melanosis by Dr. Vibha Shah

Dr. Vibha Shah shares insights on Periorbital Melanosis

button
27 May

Rotational Therapy for Androgenetic Alopecia by Dr. Prakash Dhulange

Dr. Prakash Dhulange shares insights on Rotational Therapy for Androgenetic Alopecia

button
27 May

Acne Vulgaris by Dr. Raghav Gupta

Dr. Raghav Gupta shares his insights on Acne Vulgaris

button

Courses

No results found.

Medshorts

2Min Read
21 Jun

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

button
2Min Read
21 Jun

Comparison of topical permethrin 5% vs. benzyl benzoate 25% in managing scabies

A recent study found that the application of benzyl benzoate 25% (BB) has proven to be highly effective in treating scabies, with a significant cure rate and acceptable tolerability, when compared to the use of topical permethrin 5%. This study’s results were published in The British journal of dermatology.

In this double-blinded, randomized controlled trial, a total of 110 patients with dermoscopy-verified scabies infestation were included. These patients were then randomly assigned to receive topical permethrin 5% (n=55) or topical BB 25% (n=55). Both treatments were applied daily for three consecutive days. The treatment outcomes were assessed through dermoscopy during a follow-up visit after three weeks.

At the end of the study, the dermoscopy-verified cure rate was 27% in the permethrin group and 87% in the BB group following treatment. Permethrin 5% cream demonstrated outstanding tolerability and safety, whereas the BB emulsion caused a burning sensation in 43% of individuals.

In most cases of scabies, topical permethrin was found to be ineffective, whereas BB demonstrated a remarkable cure rate and acceptable tolerability. Considering the decreased sensitivity of scabies mites to permethrin 5%, the above study findings suggest that BB may be the appropriate first-line treatment for treating scabies.

button
1Min Read
18 Jun

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

button
1Min Read
18 Jun

Remibrutinib is safe and effective for chronic spontaneous urticaria

 A recent study suggests that remibrutinib is effective for the treatment of chronic spontaneous urticaria (CSU). The results of this study were published in the Journal of Allergy and Clinical Immunology. 

Remibrutinib is a highly selective, oral, novel covalent Bruton tyrosine kinase inhibitor. This randomized, double-blind, placebo-controlled, phase 2b dose-finding trial evaluated the safety and efficacy of remibrutinib. The study included 311 patients inadequately controlled with second-generation H1-antihistamines, with at least moderately active CSU, with or without prior anti-IgE treatment. The study participants were randomized to receive remibrutinib at different doses ranging from 10 mg to 100mg for 12 weeks. The main end points were weekly Urticaria Activity Score change from baseline at week 4 and safety.

Remibrutinib at all doses showed reduced symptom score from week 1 until week 12, with weekly Urticaria Activity Score change from baseline at week 4.

Therefore, the study results indicate that remibrutinib is highly effective in the treatment of CSU, with a rapid onset of action and a favorable safety profile.

button
2Min Read
05 Apr

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

button
2Min Read
05 Apr

Adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel effective in preventing worsening of atrophic acne scars

According to a recent study, maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris. This study was published in the Journal of Dermatology.

This randomized study included 126 patients, who were randomized to receive adapalene/benzoyl peroxide (n = 40), benzoyl peroxide (n = 44), and control (without maintenance treatment drugs (n = 42). Among these patients, 111 individuals completed a trial lasting for 24 weeks. The primary endpoint and one of the secondary endpoints of the study were treatment success rate (the percentage of patients in whom the number of inflammatory lesions was maintained at ≤10) and the rate of change in the number of atrophic scars, respectively.

At week 24, the treatment success rate was 89.2% in the adapalene/benzoyl peroxide group, 87.5% in the benzoyl peroxide group, and 47.4% in the control group. The treatment success rates were significantly higher in the adapalene/benzoyl peroxide and benzoyl peroxide groups compared to the control group. Additionally, the rate of change in the number of atrophic scars showed significant improvement from the baseline in the adapalene/benzoyl peroxide and benzoyl peroxide groups.

Based on these findings, it may be suggested that maintenance therapy using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel is effective in preventing the worsening of scars in patients with acne vulgaris.

button